Here's Where Novavax May Beat Moderna and Pfizer
Early in the coronavirus vaccine race, Novavax (NASDAQ: NVAX) seemed to have secured the third spot behind rivals Moderna (NASDAQ: MRNA) and Pfizer. The U.S. Food and Drug Administration (FDA) authorized the Moderna and Pfizer vaccines in December. And it looked like Novavax would submit its U.S. authorization request in the first half of this year.
But Novavax fell behind as materials shortages hurt its manufacturing ramp up. Now, the company expects to file for authorization in the fourth quarter.
But there's an important area where Novavax has stepped ahead of its bigger rivals. And this particular area actually may be worth billions of dollars in revenue in the years to come. Let's take a closer look at what Novavax is doing now that may lead to victory down the road.
Source Fool.com
